TNFRSF21抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08250(TNFRSF21 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08250(TNFRSF21 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of TNFRSF21 Antibody**

TNFRSF21 (tumor necrosis factor receptor superfamily member 21), also known as DR6 or CD358. is a transmembrane protein belonging to the TNF receptor family. It contains extracellular cysteine-rich domains, a transmembrane region, and an intracellular death domain. Functionally, TNFRSF21 is implicated in regulating apoptosis, immune responses, and neuronal development through interactions with ligands like amyloid precursor protein (APP). Its signaling pathways involve caspase activation and modulation of NF-κB or JNK, influencing cell survival, inflammation, and tissue homeostasis.

Antibodies targeting TNFRSF21 are vital tools for studying its expression, localization, and mechanistic roles. These antibodies, including monoclonal and polyclonal types, are used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. Researchers employ them to investigate TNFRSF21's involvement in diseases such as cancer, neurodegenerative disorders (e.g., Alzheimer’s), and autoimmune conditions, where dysregulated TNFRSF21 signaling may contribute to pathogenesis.

Additionally, TNFRSF21 antibodies hold therapeutic potential. Blocking or agonizing antibodies are explored for modulating immune responses or targeting cancer cells. However, challenges remain in understanding context-dependent signaling and optimizing specificity. Overall, TNFRSF21 antibodies are crucial for unraveling its biological complexity and advancing translational research.